AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Middle East Conflict Impacts Australia and New Zealand Businesses 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
VANCOUVER, British Columbia, May 02, 2018 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming Deutsche Bank 43rd Annual Healthcare Conference in Boston on Wednesday, May 9th 2018.
Aquinox Presentation Details
Date: Wednesday, May 9th 2018
Time: 6:20 am Pacific Time / 9:20 am Eastern Time
Location: Boston, MA – Intercontinental Hotel Boston
A live webcast and archive of the event will be available at:
https://edge.media-server.com/m6/p/oiye7bcp
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
